Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer

Two decades of clinical cancer research with dendritic cell (DC)-based vaccination have proved that this type of personalized medicine is safe and has the capacity to improve survival, but monotherapy is unlikely to cure the cancer. Designed to empower the patient’s antitumor immunity, huge research...

Descripción completa

Detalles Bibliográficos
Autores principales: Versteven, Maarten, Van den Bergh, Johan M. J., Marcq, Elly, Smits, Evelien L. J., Van Tendeloo, Viggo F. I., Hobo, Willemijn, Lion, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863527/
https://www.ncbi.nlm.nih.gov/pubmed/29599770
http://dx.doi.org/10.3389/fimmu.2018.00394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863527/
https://www.ncbi.nlm.nih.gov/pubmed/29599770
http://dx.doi.org/10.3389/fimmu.2018.00394

Ejemplares similares